JP2005514927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005514927A5 JP2005514927A5 JP2003560171A JP2003560171A JP2005514927A5 JP 2005514927 A5 JP2005514927 A5 JP 2005514927A5 JP 2003560171 A JP2003560171 A JP 2003560171A JP 2003560171 A JP2003560171 A JP 2003560171A JP 2005514927 A5 JP2005514927 A5 JP 2005514927A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- oligonucleotide
- double
- library
- stranded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 256
- 229920001184 polypeptide Polymers 0.000 claims description 255
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 255
- 238000000034 method Methods 0.000 claims description 245
- 108091034117 Oligonucleotide Proteins 0.000 claims description 205
- 150000007523 nucleic acids Chemical class 0.000 claims description 174
- 102000039446 nucleic acids Human genes 0.000 claims description 172
- 108020004707 nucleic acids Proteins 0.000 claims description 172
- 108091033319 polynucleotide Proteins 0.000 claims description 135
- 102000040430 polynucleotide Human genes 0.000 claims description 135
- 239000002157 polynucleotide Substances 0.000 claims description 135
- 230000027455 binding Effects 0.000 claims description 88
- 239000000427 antigen Substances 0.000 claims description 82
- 102000036639 antigens Human genes 0.000 claims description 82
- 108091007433 antigens Proteins 0.000 claims description 82
- 108020004705 Codon Proteins 0.000 claims description 77
- 108091008146 restriction endonucleases Proteins 0.000 claims description 59
- 238000012217 deletion Methods 0.000 claims description 52
- 230000037430 deletion Effects 0.000 claims description 52
- 125000003729 nucleotide group Chemical group 0.000 claims description 52
- 239000002773 nucleotide Substances 0.000 claims description 51
- 238000003780 insertion Methods 0.000 claims description 50
- 230000037431 insertion Effects 0.000 claims description 50
- 108091026890 Coding region Proteins 0.000 claims description 41
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 41
- 239000000758 substrate Substances 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000003550 marker Substances 0.000 claims description 10
- 230000003252 repetitive effect Effects 0.000 claims description 7
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 230000003100 immobilizing effect Effects 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 4
- 230000009870 specific binding Effects 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 230000003362 replicative effect Effects 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 238000002703 mutagenesis Methods 0.000 description 37
- 231100000350 mutagenesis Toxicity 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 26
- 230000003321 amplification Effects 0.000 description 20
- 238000003199 nucleic acid amplification method Methods 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 18
- 238000003752 polymerase chain reaction Methods 0.000 description 18
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 108020000946 Bacterial DNA Proteins 0.000 description 6
- 230000017730 intein-mediated protein splicing Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000033607 mismatch repair Effects 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 108020001738 DNA Glycosylase Proteins 0.000 description 3
- 102000028381 DNA glycosylase Human genes 0.000 description 3
- 108091061960 Naked DNA Proteins 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 102100026406 G/T mismatch-specific thymine DNA glycosylase Human genes 0.000 description 2
- 101710153534 G/U mismatch-specific DNA glycosylase Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 108010035344 Thymine DNA Glycosylase Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 108010093801 endodeoxyribonuclease BstNBI Proteins 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 125000005642 phosphothioate group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033590 base-excision repair Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- -1 cationic lipid Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34876402P | 2002-01-14 | 2002-01-14 | |
| US34860902P | 2002-01-14 | 2002-01-14 | |
| US34876102P | 2002-01-14 | 2002-01-14 | |
| US10/077,474 US6673552B2 (en) | 2002-01-14 | 2002-02-14 | Methods for purifying annealed double-stranded oligonucleotides lacking base pair mismatches or nucleotide gaps |
| PCT/US2003/001189 WO2003060084A2 (en) | 2002-01-14 | 2003-01-14 | Methods for making polynucleotides and purifying double-stranded polynucleotides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005514927A JP2005514927A (ja) | 2005-05-26 |
| JP2005514927A5 true JP2005514927A5 (enExample) | 2006-03-02 |
Family
ID=34658146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003560171A Abandoned JP2005514927A (ja) | 2002-01-14 | 2003-01-14 | ポリヌクレオチドの製造方法及び二本鎖ポリヌクレオチドの精製方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050130156A1 (enExample) |
| EP (1) | EP1472373A4 (enExample) |
| JP (1) | JP2005514927A (enExample) |
| AU (1) | AU2003217207A1 (enExample) |
| CA (1) | CA2473434A1 (enExample) |
| WO (1) | WO2003060084A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7563600B2 (en) | 2002-09-12 | 2009-07-21 | Combimatrix Corporation | Microarray synthesis and assembly of gene-length polynucleotides |
| AU2005295351A1 (en) * | 2004-10-18 | 2006-04-27 | Codon Devices, Inc. | Methods for assembly of high fidelity synthetic polynucleotides |
| US20070122817A1 (en) * | 2005-02-28 | 2007-05-31 | George Church | Methods for assembly of high fidelity synthetic polynucleotides |
| US20070231805A1 (en) * | 2006-03-31 | 2007-10-04 | Baynes Brian M | Nucleic acid assembly optimization using clamped mismatch binding proteins |
| US8053191B2 (en) | 2006-08-31 | 2011-11-08 | Westend Asset Clearinghouse Company, Llc | Iterative nucleic acid assembly using activation of vector-encoded traits |
| US9115352B2 (en) * | 2008-03-31 | 2015-08-25 | Sloning Biotechnology Gmbh | Method for the preparation of a nucleic acid library |
| WO2011056872A2 (en) | 2009-11-03 | 2011-05-12 | Gen9, Inc. | Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly |
| WO2011066185A1 (en) | 2009-11-25 | 2011-06-03 | Gen9, Inc. | Microfluidic devices and methods for gene synthesis |
| WO2011085075A2 (en) | 2010-01-07 | 2011-07-14 | Gen9, Inc. | Assembly of high fidelity polynucleotides |
| WO2012064975A1 (en) | 2010-11-12 | 2012-05-18 | Gen9, Inc. | Protein arrays and methods of using and making the same |
| CA2817697C (en) | 2010-11-12 | 2021-11-16 | Gen9, Inc. | Methods and devices for nucleic acids synthesis |
| WO2012092374A2 (en) * | 2010-12-31 | 2012-07-05 | Short Jay M | Express humanization of antibodies |
| JP2014526899A (ja) | 2011-08-26 | 2014-10-09 | ジェン９・インコーポレイテッド | 核酸の高忠実度アセンブリのための組成物および方法 |
| US9150853B2 (en) | 2012-03-21 | 2015-10-06 | Gen9, Inc. | Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis |
| CA2871505C (en) | 2012-04-24 | 2021-10-12 | Gen9, Inc. | Methods for sorting nucleic acids and multiplexed preparative in vitro cloning |
| WO2014004393A1 (en) | 2012-06-25 | 2014-01-03 | Gen9, Inc. | Methods for nucleic acid assembly and high throughput sequencing |
| KR102160389B1 (ko) | 2013-08-05 | 2020-09-28 | 트위스트 바이오사이언스 코포레이션 | 드 노보 합성된 유전자 라이브러리 |
| CA2975852A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| KR20180050411A (ko) | 2015-09-18 | 2018-05-14 | 트위스트 바이오사이언스 코포레이션 | 올리고핵산 변이체 라이브러리 및 그의 합성 |
| WO2017053450A1 (en) | 2015-09-22 | 2017-03-30 | Twist Bioscience Corporation | Flexible substrates for nucleic acid synthesis |
| EP4664304A3 (en) | 2016-09-21 | 2026-01-21 | Atlas Data Storage, Inc. | Nucleic acid based data storage |
| WO2018156792A1 (en) | 2017-02-22 | 2018-08-30 | Twist Bioscience Corporation | Nucleic acid based data storage |
| CA3056388A1 (en) | 2017-03-15 | 2018-09-20 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
| IL271205B2 (en) | 2017-06-12 | 2025-02-01 | Twist Bioscience Corp | Methods for assembling continuous nucleic acids |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| CN111566125A (zh) | 2017-09-11 | 2020-08-21 | 特韦斯特生物科学公司 | Gpcr结合蛋白及其合成 |
| CN111565834B (zh) | 2017-10-20 | 2022-08-26 | 特韦斯特生物科学公司 | 用于多核苷酸合成的加热的纳米孔 |
| IL312616B2 (en) | 2018-01-04 | 2025-08-01 | Twist Bioscience Corp | Dna-based digital information storage |
| EP3814497A4 (en) | 2018-05-18 | 2022-03-02 | Twist Bioscience Corporation | POLYNUCLEOTIDES, REAGENTS AND METHODS FOR NUCLEIC ACID HYBRIDIZATION |
| EP3902816A4 (en) | 2018-12-26 | 2022-09-14 | Twist Bioscience Corporation | HIGH-PRECISION DE NOVO POLYNUCLEOTIDE SYNTHESIS |
| KR20210144698A (ko) | 2019-02-26 | 2021-11-30 | 트위스트 바이오사이언스 코포레이션 | 항체 최적화를 위한 변이 핵산 라이브러리 |
| CA3131689A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
| EP3987019A4 (en) | 2019-06-21 | 2023-04-19 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| CN115023440B (zh) | 2019-09-23 | 2025-09-12 | 特韦斯特生物科学公司 | 结合CD3ε的抗体 |
| US12091777B2 (en) | 2019-09-23 | 2024-09-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for CRTH2 |
| AU2020400030B2 (en) | 2019-12-09 | 2026-05-21 | Twist Bioscience Corporation | Variant nucleic acid libraries for adenosine receptors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5556750A (en) * | 1989-05-12 | 1996-09-17 | Duke University | Methods and kits for fractionating a population of DNA molecules based on the presence or absence of a base-pair mismatch utilizing mismatch repair systems |
| US5750335A (en) * | 1992-04-24 | 1998-05-12 | Massachusetts Institute Of Technology | Screening for genetic variation |
| US6027877A (en) * | 1993-11-04 | 2000-02-22 | Gene Check, Inc. | Use of immobilized mismatch binding protein for detection of mutations and polymorphisms, purification of amplified DNA samples and allele identification |
| US6294325B1 (en) * | 1996-07-05 | 2001-09-25 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of thermostable multi genes and proteins and uses thereof |
| AU5195398A (en) * | 1996-10-25 | 1998-05-15 | Advanced Research And Technology Institute, Inc. | Dna sequences encoding fusions of dna repair proteins and uses thereof |
| WO1999010369A1 (en) * | 1997-08-28 | 1999-03-04 | Thomas Jefferson University | Compositions, kits, and methods for effecting adenine nucleotide modulation of dna mismatch recognition proteins |
| US6033861A (en) * | 1997-11-19 | 2000-03-07 | Incyte Genetics, Inc. | Methods for obtaining nucleic acid containing a mutation |
| US6297010B1 (en) * | 1998-01-30 | 2001-10-02 | Genzyme Corporation | Method for detecting and identifying mutations |
| US7033781B1 (en) * | 1999-09-29 | 2006-04-25 | Diversa Corporation | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating |
| US6365355B1 (en) * | 2000-03-28 | 2002-04-02 | The Regents Of The University Of California | Chimeric proteins for detection and quantitation of DNA mutations, DNA sequence variations, DNA damage and DNA mismatches |
| US6673552B2 (en) * | 2002-01-14 | 2004-01-06 | Diversa Corporation | Methods for purifying annealed double-stranded oligonucleotides lacking base pair mismatches or nucleotide gaps |
-
2003
- 2003-01-14 JP JP2003560171A patent/JP2005514927A/ja not_active Abandoned
- 2003-01-14 CA CA002473434A patent/CA2473434A1/en not_active Abandoned
- 2003-01-14 WO PCT/US2003/001189 patent/WO2003060084A2/en not_active Ceased
- 2003-01-14 US US10/501,592 patent/US20050130156A1/en not_active Abandoned
- 2003-01-14 EP EP03713244A patent/EP1472373A4/en not_active Withdrawn
- 2003-01-14 AU AU2003217207A patent/AU2003217207A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4015193B2 (ja) | 反復的選択および組換えにより所望の特徴を有するポリヌクレオチドを作製する方法 | |
| JP4067516B2 (ja) | ランダムフラグメント化および再組立によるｄｎａ変異誘発 | |
| JP3344584B2 (ja) | 組換えライブラリースクリーニング法 | |
| KR101051245B1 (ko) | 시험관내 펩타이드 발현 라이브러리 | |
| EP1266025B1 (en) | Protein scaffolds for antibody mimics and other binding proteins | |
| US20100021477A1 (en) | DESIGN AND GENERATION OF HUMAN DE NOVO pIX PHAGE DISPLAY LIBRARIES | |
| JP2000514651A (ja) | 合成または増幅過程をブロックまたは中断することにより製造されたポリヌクレオチドによるｄｎａのシャッフリング方法 | |
| JPH06505866A (ja) | 結合タンパク質の最適化 | |
| JPH08506487A (ja) | 全合成親和性試薬 | |
| AU2001241850A1 (en) | Protein scaffolds for antibody mimics and other binding proteins | |
| WO2010039852A2 (en) | Improved antibody libraries | |
| JP2003505041A (ja) | 固体支持体担体を用いる試験管内選択及びポリペプチドの任意の同定 | |
| JP2001514498A (ja) | 多数のｄｎａ断片の同時連結方法 | |
| US5891637A (en) | Construction of full length cDNA libraries | |
| US7527954B2 (en) | Method for in vitro evolution of polypeptides | |
| KR100491810B1 (ko) | 무작위단편화및재조립에의한dna돌연변이유발방법 | |
| EP1576154B1 (en) | In vivo affinity maturation scheme | |
| AU2013352067A1 (en) | Preparation of gene-specific templates for the use in single primer amplification | |
| US20180245070A1 (en) | Dna display and methods thereof | |
| WO2025081084A1 (en) | Improved methods for determining sequences of nucleic acids | |
| JPH06205691A (ja) | モノクローナル抗体の製造方法 | |
| AU2003287780A1 (en) | In vivo affinity maturation scheme |